• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - 2012 Product Image

BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - 2012

  • ID: 2141827
  • May 2012
  • 72 pages
  • Global Markets Direct

BioCryst Pharmaceuticals, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the BioCryst Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, BioCryst Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from BioCryst Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- BioCryst Pharmaceuticals, Inc. - Brief BioCryst Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of BioCryst Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy READ MORE >



List of Tables
List of Figures
BioCryst Pharmaceuticals, Inc. Snapshot
BioCryst Pharmaceuticals, Inc. Overview
Key Information
Key Facts
BioCryst Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
BioCryst Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
BioCryst Pharmaceuticals, Inc. – Pipeline Products Glance
BioCryst Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
BioCryst Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
BioCryst Pharmaceuticals, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
BioCryst Pharmaceuticals, Inc. – Drug Profiles
BCX4161
Product Description
Mechanism of Action
R&D Progress
BCX4208
Product Description
Mechanism of Action
R&D Progress
BCX4208 + Allopurinol
Product Description
Mechanism of Action
R&D Progress
BCX5191
Product Description
Mechanism of Action
R&D Progress
Peramivir
Product Description
Mechanism of Action
R&D Progress
BioCryst Pharmaceuticals, Inc. – Pipeline Analysis
BioCryst Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
BioCryst Pharmaceuticals, Inc. – Pipeline Products By Target
BioCryst Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
BioCryst Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action
BioCryst Pharmaceuticals, Inc. – Recent Pipeline Updates
BioCryst Pharmaceuticals, Inc. - Dormant Projects
BioCryst Pharmaceuticals, Inc. – Company Statement
BioCryst Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
BioCryst Pharmaceuticals, Inc., Recent Developments
BioCryst Pharmaceuticals, Inc.- Press Release
Feb 15, 2012: BioCryst Announces Promising Results From Preclinical Studies Of BCX5191 For Hepatitis C
Jan 08, 2012: BioCryst Announces Positive Results From Ongoing BCX4208 Phase IIb Study In Patients With Gout
Nov 05, 2009: BioCryst's Partner Shionogi Files For Regulatory Approval Of Peramivir In Japan
Sep 28, 2009: BioCryst Announces Initiation of Phase 2 Study of BCX4208 for the Treatment of Gout
Financial Deals Landscape
BioCryst Pharmaceuticals, Inc., Deals Summary
BioCryst Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
BioCryst Pharma Enters Into Co-Marketing Agreement With Merck Serono
BioCryst Pharma Enters Into Co-Marketing Agreement With Hikma Pharma
BioCryst Enters Into A Co-Marketing Agreement With NT Pharma
BioCryst Pharma Enters Into An Agreement With SCOLR Pharma
BioCryst Pharma Enters Into Co-Development Agreement With Green Cross
Mundipharma Enters Into Agreement With BioCryst Pharma
Roche Signs An Agreement With BioCryst Pharma
Licensing Agreements
Biocryst Pharma Amends Licensing Agreement With Shionogi
BioCryst Pharma Enters Into Licensing Agreement With Shionogi
Equity Offering
BioCryst Pharma Files Registration Statement For Public Offering Of $70 Million
BioCryst Pharma Completes Public Offering Of $49 Million
BioCryst Completes Private Placement Of $65.3 Million
BioCryst Pharma Completes Private Placement Of $30 Million
BioCryst Pharma Completes Private Placement Of $24 Million
BioCryst Pharma Completes Private Placement Of $21.43 Million
Debt Offering
BioCryst Pharma Completes Private Placement Of Senior Secured Notes Due 2020 For $30 Million
Asset Transactions
Southern Research Institute To Acquire Bioanalytical Lab Assets From BioCryst Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
BioCryst Pharmaceuticals, Inc., Key Information
BioCryst Pharmaceuticals, Inc., Key Facts
BioCryst Pharmaceuticals, Inc. – Pipeline by Indication, 2012
BioCryst Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
BioCryst Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
BioCryst Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
BioCryst Pharmaceuticals, Inc. – Phase III, 2012
BioCryst Pharmaceuticals, Inc. – Phase II, 2012
BioCryst Pharmaceuticals, Inc. – Pre-Clinical, 2012
BioCryst Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
BioCryst Pharmaceuticals, Inc. - Pipeline By Target, 2012
BioCryst Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
BioCryst Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012
BioCryst Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012
BioCryst Pharmaceuticals, Inc. - Dormant Developmental Projects,2012
BioCryst Pharmaceuticals, Inc., Other Locations
BioCryst Pharmaceuticals, Inc., Deals Summary
BioCryst Pharma Enters Into Co-Marketing Agreement With Merck Serono
BioCryst Pharma Enters Into Co-Marketing Agreement With Hikma Pharma
BioCryst Enters Into A Co-Marketing Agreement With NT Pharma
BioCryst Pharma Enters Into An Agreement With SCOLR Pharma
BioCryst Pharma Enters Into Co-Development Agreement With Green Cross
Mundipharma Enters Into Agreement With BioCryst Pharma
Roche Signs An Agreement With BioCryst Pharma
Biocryst Pharma Amends Licensing Agreement With Shionogi
BioCryst Pharma Enters Into Licensing Agreement With Shionogi
BioCryst Pharma Files Registration Statement For Public Offering Of $70 Million
BioCryst Pharma Completes Public Offering Of $49 Million
BioCryst Completes Private Placement Of $65.3 Million
BioCryst Pharma Completes Private Placement Of $30 Million
BioCryst Pharma Completes Private Placement Of $24 Million
BioCryst Pharma Completes Private Placement Of $21.43 Million
BioCryst Pharma Completes Private Placement Of Senior Secured Notes Due 2020 For $30 Million
Southern Research Institute To Acquire Bioanalytical Lab Assets From BioCryst Pharma

List of Figures
BioCryst Pharmaceuticals, Inc. – Pipeline by Indication, 2012
BioCryst Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
BioCryst Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
BioCryst Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
BioCryst Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
BioCryst Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
BioCryst Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos